AZ receives €4.75bn orders for €2.2bn
Biopharmaceutical company AstraZeneca hit a frenzied corporate bond market on Monday with a €2.2bn three tranche bond that contributed to around €6bn of primary supply that day.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: